Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY 4,410.00
-63.00 (-1.41%)
At close: Dec 5, 2025
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.11T JPY in the quarter ending September 30, 2025, a decrease of -5.38%. This brings the company's revenue in the last twelve months to 4.42T, down -2.84% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4,417.00B
Revenue Growth
-2.84%
P/S Ratio
1.58
Revenue / Employee
93.08M
Employees
47,455
Market Cap
6,966.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,213.71B |
| HOYA Corporation | 892.50B |
| Daiichi Sankyo Company | 1,978.88B |
| Otsuka Holdings | 2,418.53B |
| Astellas Pharma | 2,006.82B |
| Terumo | 1,062.42B |
| Shionogi & | 437.26B |
| Olympus | 977.65B |
Takeda Pharmaceutical Company News
- 1 day ago - Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies - PRNewsWire
- 14 days ago - US FDA investigates death tied to Takeda's blood disorder drug - Reuters
- 14 days ago - Takeda blood disorder therapy Adzynma linked to patient death: FDA - Seeking Alpha
- 15 days ago - Innovent, first Chinese firm to market weight-loss drug, joins Hang Seng Index - South China Morning Post
- 17 days ago - Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery - GlobeNewsWire
- 24 days ago - Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga
- 4 weeks ago - Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy - Nasdaq
- 4 weeks ago - Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy - Business Wire